67,644 Shares in Novavax, Inc. (NASDAQ:NVAX) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in Novavax, Inc. (NASDAQ:NVAX) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 67,644 shares of the biopharmaceutical company’s stock, valued at approximately $544,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Spire Wealth Management bought a new position in shares of Novavax during the fourth quarter valued at about $29,000. New Age Alpha Advisors LLC purchased a new position in shares of Novavax during the fourth quarter valued at approximately $35,000. KBC Group NV lifted its stake in Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 3,917 shares during the period. TigerOak Management L.L.C. bought a new stake in Novavax in the fourth quarter valued at $86,000. Finally, AlphaQuest LLC raised its holdings in Novavax by 290.1% in the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 7,940 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors.

Novavax Trading Up 11.5 %

NASDAQ NVAX opened at $6.64 on Friday. The stock’s fifty day moving average price is $6.90 and its 200-day moving average price is $8.06. The stock has a market cap of $1.07 billion, a P/E ratio of -2.94, a P/E/G ratio of 2.85 and a beta of 3.21. Novavax, Inc. has a 12 month low of $4.43 and a 12 month high of $23.86.

Novavax (NASDAQ:NVAX) last issued its earnings results on Friday, May 9th. The biopharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $2.74. During the same quarter in the prior year, the company posted ($1.05) earnings per share. Novavax’s quarterly revenue was up 610.3% on a year-over-year basis. As a group, analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. BTIG Research initiated coverage on shares of Novavax in a research note on Friday, February 28th. They issued a “buy” rating and a $19.00 price target for the company. TD Cowen raised Novavax to a “hold” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $18.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.